Status:
ACTIVE_NOT_RECRUITING
The Impact of Genetic Polymorphism on the Echocardiographic Parameters and Cardiac Fibrosis Markers in Response to Empagliflozin Treatment Among Patients With Heart Failure
Lead Sponsor:
Ain Shams University
Conditions:
Heart Failure
Eligibility:
All Genders
18-80 years
Brief Summary
It is important to assess the implications of genetic variants of the TGF-β1 gene in patients with HFrEF and the association of this polymorphism with treatment response to SGLT2I. Therefore, by corre...
Detailed Description
Cardiovascular diseases are the leading cause of morbidity and mortality worldwide. According to the American heart association (AHA) over 19.1 million deaths worldwide in 2020 were attributed to CVD....
Eligibility Criteria
Inclusion
- Heart failure patients NYHA class II to IV.
- Treatment with beta blockers, MRAs, ACEIs in addition to empagliflozin.
- Age of 18 years to 80 years.
- Written informed consent of the subject to participate in the study.
Exclusion
- Contraindication to empagliflozin: pregnancy, hypersensitivity, and severe renal impairment.
- CABG or valve surgery within 3 months.
- Mild-to-severe valvular stenosis or severe (grade III/IV) valvular regurgitation
- Pregnant or nursing women.
Key Trial Info
Start Date :
July 30 2023
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
October 1 2025
Estimated Enrollment :
92 Patients enrolled
Trial Details
Trial ID
NCT06503601
Start Date
July 30 2023
End Date
October 1 2025
Last Update
July 16 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Ain shams university
Cairo, Egypt, 11315